BioSpace News Archive

Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Steven Gygi, Ph.D., will join its scientific advisory board.

Greenleaf Health, a leading Food and Drug Administration regulatory consulting firm, announces that the firm has expanded its compliance and manufacturing portfolio to include Good Clinical Practice services.

The Foundation takes a look back at the ground-breaking research in dermatology that has improved the quality of life for men, women and children

Emad Rizk, M.D., chairman, president, and chief executive officer of Cotiviti, will be a featured panelist today at the Bipartisan Policy Center’s event, “The Future of AI,” which will examine the role of artificial intelligence (AI) in the U.S. healthcare and financial systems and how public policy should adopt to changing realities.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the presentation of new customer, company and collaborator data using the Twist Bioscience target enrichment and library preparation products for next-generation sequencing (NGS).

Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has announced the launch of ExomeCG, a new product to simplify the generation and interpretation of molecular and cytogenomic data.

Canadian employees are at high risk of medication related problems, leading to serious health risks, increased absenteeism in the workplace and high disability costs for employers, according to new research.

StemoniX, Inc., a leader in human microOrgan® platforms for drug discovery and development, today announced the appointment of Andrew (Andy) D. C. LaFrence, CPA, as Chief Financial Officer (CFO)

Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic diseases, today announced that enrollment is now open for a Phase I/II trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy (brain injury caused by oxygen deprivation to the brain)

Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA), one of the key drivers of the most aggressive cancers, today announced presentations at two upcoming conferences in October: